Efficacy and toxicity of radioimmunotherapy with 90Y-DOTA-peptide-ChL6 for PC3-tumored mice

Prostate

Volumn 44, Issue 3, 2000, Pages 187-192

  O'Donnell, Robert T ^a,b,c   DeNardo, Sally J ^a   DeNardo, Gerald L ^a   Miers, Laird ^a   Lamborn, Kathleen R ^a   Kukis, David L ^a   Meyers, Frederick J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Radiodiagnosis and Therapy   (United States)

Author keywords

Chimeric L6; Nude mice; PC3; Prostate cancer; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; MONOCLONAL ANTIBODY; YTTRIUM 90;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOTHERAPY; SURVIVAL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; LEUKOCYTE COUNT; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGOPEPTIDES; PLATELET COUNT; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; SPECIFIC PATHOGEN-FREE ORGANISMS; TUMOR CELLS, CULTURED; WHOLE-BODY COUNTING; YTTRIUM; YTTRIUM RADIOISOTOPES;

EID: 0034256017     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20000801)44:3<187::AID-PROS2>3.0.CO;2-C     Document Type: Article

References (32)

1. Hellstrom I, Beaumier PL, Hellstrom KE. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci USA 1986;83:7059-7063.
2. O'Donnell RT, DeNardo SJ, Shi XB, Mirick GR, DeNardo GL, Kroger LA, Meyers FJ. L6 monoclonal antibody binds prostate cancer. Prostate 1998;37:91-97.
3. Marken JS, Bajorath J, Edwards CP, Farr AG, Schieven GL, Hellstrom I, Hellstrom KE, Aruffo A. Membrane topology of the L6 antigen and identification of the protein epitope recognized by the L6 monoclonal antibody. J Biol Chem 1994;269:7397-7401.
4. Howell LP, DeNardo SJ, Levy N, Lund J, DeNardo GL. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: a comparative study. Int J Biol Markers 1995;10:126-135.
5. Adams GP, DeNardo SJ, Amin A, Kroger LA, DeNardo GL, Hellstrom I, Hellstrom KE. Comparison of the pharmacokinetics in mice and the biological activity of murine L6 and human-mouse chimeric Ch-L6 antibody. Antibody Immunoconj Radiopharm 1992;5:81-95.
6. DeNardo SJ, O'Grady LF, Macey DJ, Kroger LA, DeNardo GL, Lamborn KR, Levy NB, Mills SL, Hellstrom I, Hellstrom KE. Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Int J Rad Appl Instrum [B] 1991;18:621-631.
7. DeNardo SJ, O'Grady LF, Richman CM, Goldstein DS, O'Donnell RT, DeNardo DA, Kroger LA, Lamborn KR, Hellstrom KE, Hellstrom I, DeNardo GL. Radioimmunotherapy for advanced breast cancer using 1-131-ChL6 antibody. Anticancer Res 1997;17:1745-1752.
8. DeNardo SJ, Mirick GR, Kroger LA, O'Grady LF, Erickson KL, Yuan A, Lamborn KR, Hellstrom I, Hellstrom KE, DeNardo GL. The biologic window for chimeric L6 radioimmunotherapy. Cancer [Suppl] 1994;73:1023-1032.
9. DeNardo SJ, Kukis DL, Miers L, Winthrop MD, Kroger LA, Salako QA, Shen S, Lamborn KR, Gumerlock PH, Meares CF, DeNardo GL. Yttrium-90-DOTA-peptide ChL6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J Nucl Med 1998;39:842-849.
10. DeNardo SJ, Zhong G-R, Salako Q, Li M, DeNardo GL, Meares CF. Pharmacokinetics of chimeric L6 conjugated to indium-111 and yttrium-90-DOTA-peptide in tumor bearing mice. J Nucl Med 1995;36:829-836.
11. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res 1990;50:2330-2336.
12. DeNardo GL, DeNardo SJ, Miyao NP, Mills SL, Peng JS, O'Grady LF, Epstein AL, Young WC. Non-dehalogenation mechanisms for excretion of radioiodine after administration of labeled antibodies. Int J Biol Markers 1988;3:1-9.
13. Liu AY, Robinson RR, Hellstrom KE, Murray EDJ, Chang CP, Hellstrom I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 1987;84: 3439-3443.
14. DeNardo SJ, Richman CM, Kukis DL, Shen S, Lamborn KR, Miers LA, Kroger LA, DeNardo GL. Synergistic therapy for breast cancer: development of a clinical protocol for R1T and taxol based on curative therapy of xenografted tumors and Y-90 ChL6 patient dosimetry. J Nucl Med 1998;39:246.
15. Kaighn M, Narayan K, Ohnuki Y, Lechner J, Jones L. Establishment and characterization of a human prostrate carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
16. Arah IN, Song K, Seth P, Cowan KH, Sinha BK. Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells. Anticancer Res 1998;18: 1845-1849.
17. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997;57:1758-1768.
18. 67Cu-21T-BAT-Lym-1 radioimmunoconjugate in mice implanted with Burkitt's lymphoma (Raji). Clin Cancer Res 1997;3:71-79.
19. 131I-Lym-1 in patients with B-cell malignancies. Nucl Med Commun 1993;14:587-595.
20. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-7495.
21. Harris C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-1455.
22. Meyn RE. Apoptosis and response to radiation: implications for radiation therapy. Oncology 1997;11:349-356.
23. DeNardo SJ, Gumerlock PH, Winthrop MD, Mack PC, Chi SG, Lamborn KR, Shen S, Miers LA, deVere White RW, DeNardo GL. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression. Cancer Res [Suppl] 1995;55:5837-5841.
24. O'Donoghue JA. The impact of tumor cell proliferation in radioimmunotherapy. Cancer 1994;73:974-980.
25. Goodman GE, Hellstrom I, Brodzinsky L, Nicaise C, Kulander B, Hummel D, Hellstrom KE. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian and lung cancer. J Clin Oncol 1990;8:1083-1092.
26. DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DC, Meares CF, DeNardo GL. Synergy of taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci USA 1997;94:4000-4004.
27. Deshpande SV, DeNardo SJ, Kukis DL, Moi MK, McCall MJ, DeNardo GL, Meares CF. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990;31:473-479.
28. DeNardo GL, Kroger LA, DeNardo SJ, Miers LA, Salako Q, Kukis DL, Fand I, Shen S, Renn O, Meares CF. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer 1994;73:1012-1022.
29. Wong JY, Williams LE, Yamauchi DM, Odom-Maryon T, Esteban JM, Neumaier M, Wu AM, Johnson DK, Primus FJ, Shively JE. Initial experience evaluating 90yttrium-radiolabeled anticarcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial. Cancer Res 1995;55:5929-5934.
30. DeNardo SJ, Richman CM, Goldstein DS, Shen S, Salako QA, Kukis DL, Meares CF, Yuan A, Welborn JL, DeNardo GL. Yttrium-90/Indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res 1997;17:1735-1744.
31. DeNardo GL, Kroger LA, Meares CF, Richman CM, Salako QA, Shen S, Lamborn KR, Peterson JJ, Miers LA, Zhong GR, De-Nardo SJ. Comparison of DOTA-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 21T-BAD-ChL6 in breast cancer xenografts. Clin Cancer Res 1998;4:2483-2490.
32. DeNardo SJ, Kroger LA, Lamborn KR, Miers LA, Kukis DL, O'Donnell R, Richman C, DeNardo GL. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer [Suppl] 1997;80:2583-2590.